Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1992-8-26
|
pubmed:abstractText |
The interdependence of blunted T cell proliferation induced by anti-CD3 monoclonal antibodies (mAb) and the preactivation of T lymphocytes (CD25+) in ESRD patients was investigated in this study. We focused on the density of IL-2 (CD25) receptors [IL-2R] on the lymphocyte surface rather than enumeration of IL-2R positive cells. The effect of exogenous IL-2 on these parameters was also tested. Blunted T lymphocyte proliferation induced by anti-CD3 mAb is only partially corrected by addition of exogenous IL-2 after 24 hrs. Freshly isolated uremic CD4 T cells show higher percentage of IL-2 positive cells and a higher IL-2R density on the cell surface compared to controls. However, after anti-CD3 mAb stimulation the number of IL-2R positive cells and IL-2R density in CD4 T subset was significantly lower than in samples from normal donors. Exogenous IL-2 had no influence on IL-2R expression on CD4 cells in uremic patients. On the other hand, following anti-CD3 mAb stimulation uremic CD8 cells reveal more IL-2R positive cells with higher IL-2R density than in controls. Moreover, exogenous IL-2 enhance IL-2R expression and density on uremic CD8 cells more than in controls. Our results suggest that the blunted T cell proliferation in ESRD patients might result from (a) preactivation of CD4 T cells, (b) diminished response of uremic CD4 T cells to IL-2, and (c) higher suppressor cells activity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Antigen, T-Cell,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0141-2760
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
34
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
171-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1668284-Adult,
pubmed-meshheading:1668284-Antibodies, Monoclonal,
pubmed-meshheading:1668284-Antigens, CD3,
pubmed-meshheading:1668284-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:1668284-Female,
pubmed-meshheading:1668284-Humans,
pubmed-meshheading:1668284-Immune Tolerance,
pubmed-meshheading:1668284-Interleukin-2,
pubmed-meshheading:1668284-Kidney Failure, Chronic,
pubmed-meshheading:1668284-Lymphocyte Activation,
pubmed-meshheading:1668284-Male,
pubmed-meshheading:1668284-Middle Aged,
pubmed-meshheading:1668284-Receptors, Antigen, T-Cell,
pubmed-meshheading:1668284-Receptors, Interleukin-2,
pubmed-meshheading:1668284-T-Lymphocyte Subsets
|
pubmed:year |
1991
|
pubmed:articleTitle |
Immunodeficiency in ESRD-patients is linked to altered IL-2 receptor density on T cell subsets.
|
pubmed:affiliation |
Department of Nephrology, University of Cologne, Germany.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|